Phenolic Acid-Functionalized Gold Nanoparticles: A Theranostic Approach to Radiosensitization and CT Contrast Enhancement in Breast Cancer
Abstract
Abstract
Purpose: Radiotherapy resistance and inadequate CT contrast sensitivity limit the efficacy of breast cancer management. This study introduces a theranostic platform based on gallic acid‑functionalized gold nanoparticles (Au@GA NPs) for dual radiosensitization and CT contrast enhancement.
Methods: Au@GA NPs were green‑synthesized using gallic acid as both reducing and capping agent. Physicochemical properties were characterized by UV‑Vis, XRD, SEM, and TEM. Cytotoxicity and radiosensitization were evaluated in MCF‑7 (cancer) and MCF‑10 (normal) cells using MTT assay combined with 6 MV X‑ray irradiation (4 Gy). CT contrast performance was compared with Omnipaque (iohexol 300) at 80, 120, and 160 kVp. Apoptosis was quantified via Annexin V‑FITC/PI flow cytometry.
Results: Spherical Au@GA NPs (~20 nm) exhibited a characteristic SPR peak at 520 nm. Selective cytotoxicity was observed: MCF‑7 viability decreased to ~68% at 200 μg/mL, while MCF‑10 remained >82%. Combination with 4 Gy irradiation reduced MCF‑7 viability to 39% (vs. 78% without NPs), demonstrating potent radiosensitization. CT attenuation of Au@GA NPs was up to 2.5‑fold higher than Omnipaque at 80 kVp. Flow cytometry revealed that the combined treatment induced 81.9% total non‑viable cells (53.7% late apoptosis), versus 25.7% for radiation alone.
Conclusion: The Au@GA NP platform offers a dual‑function strategy—enhancing tumor radiosensitivity while providing superior CT contrast—positioning it as a promising candidate for image‑guided radiotherapy (IGRT) in breast cancer.
| Files | ||
| Issue | Articles in Press | |
| Section | Original Article(s) | |
| Keywords | ||
| Gold Nanoparticles; Gallic Acid; Radiosensitization; Computed Tomography; Breast Cancer; Theranostics. | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |

